Blue Horizon International, LLC - 728085 - 05/26/2026
The FDA issued a warning letter to Blue Horizon International, LLC regarding the distribution of unapproved new drugs and unlicensed biological products.
This affects Blue Horizon International, LLC, as well as regulatory and compliance departments responsible for oversight of biological product licensing and drug approvals.
This action indicates significant regulatory risk for companies moving biological products to market without securing required Biologics License Applications (BLAs) or investigational exemptions. It suggests the FDA is actively monitoring and enforcing compliance against the commercialization of biological products that have not undergone the rigorous safety and efficacy review process. Regulatory teams should interpret this as a signal that the agency will prioritize enforcement for products circumventing the standard approval pathways.
Regulatory and clinical teams should verify that all biological products in their pipeline have appropriate BLAs or INDs in place and ensure that marketing claims do not exceed the scope of authorized use. QA teams should audit product labeling and promotional materials to ensure they do not characterize investigational products as approved drugs.
Unapproved New Drugs/Unlicensed Biological Product Violations
Open in openFDA / FDA.gov